| scholarly article | Q13442814 |
| P50 | author | Alain Saraux | Q66753982 |
| P2093 | author name string | Wendling D | |
| Guillemin F | |||
| Meyer O | |||
| Cantagrel A | |||
| Maillefert JF | |||
| Lioté F | |||
| De Bandt M | |||
| Flipo RM | |||
| Combe B | |||
| Fautrel B | |||
| Berthelot JM | |||
| Le Loët X | |||
| P2860 | cites work | Clinical guidelines: developing guidelines | Q33536430 |
| The epidemiology of rheumatoid arthritis | Q34275961 | ||
| Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis | Q34315745 | ||
| Starting a disease modifying antirheumatic drug or a biologic agent in rheumatoid arthritis: standards of practice for RA treatment. | Q34317167 | ||
| Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide | Q34550160 | ||
| Treatment strategy, disease activity, and outcome in four cohorts of patients with early rheumatoid arthritis | Q35550470 | ||
| Long-term outcome in rheumatoid arthritis: a simple algorithm of baseline parameters can predict radiographic damage, disability, and disease course at 12-year followup | Q40636485 | ||
| Early and aggressive treatment of rheumatoid arthritis patients affects the association of HLA class II antigens with progression of joint damage | Q41917696 | ||
| Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. | Q41917701 | ||
| Association of baseline levels of markers of bone and cartilage degradation with long-term progression of joint damage in patients with early rheumatoid arthritis: the COBRA study | Q44213841 | ||
| Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial | Q44985061 | ||
| American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis | Q47643186 | ||
| A proposed treatment algorithm for rheumatoid arthritis: aggressive therapy, methotrexate, and quantitative measures. | Q52003345 | ||
| Guidelines for the management of rheumatoid arthritis: 2002 Update | Q56212157 | ||
| How to diagnose rheumatoid arthritis early: A prediction model for persistent (erosive) arthritis | Q57789144 | ||
| Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis. A prospective follow-up study of 147 patients | Q67546236 | ||
| Prediction of progression of radiologic damage in newly diagnosed rheumatoid arthritis | Q71781129 | ||
| IgM, IgA, and IgG rheumatoid factors in early rheumatoid arthritis predictive of radiological progression? | Q72304712 | ||
| The diagnosis and prognosis of early arthritis: rationale for new prognostic criteria | Q77628776 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | rheumatoid arthritis | Q187255 |
| P304 | page(s) | 45-50 | |
| P577 | publication date | 2005-06-30 | |
| P1433 | published in | Annals of the Rheumatic Diseases | Q4767876 |
| P1476 | title | Clinical practice decision tree for the choice of the first disease modifying antirheumatic drug for very early rheumatoid arthritis: a 2004 proposal of the French Society of Rheumatology | |
| P478 | volume | 65 |
| Q95359397 | Q95359397 |
| Q34588972 | Abatacept treatment for rheumatoid arthritis |
| Q33355906 | Apolipoprotein A-I and platelet factor 4 are biomarkers for infliximab response in rheumatoid arthritis |
| Q47134001 | Association of MTHFR C677T and A1298C gene polymorphisms with methotrexate efficiency and toxicity in Algerian rheumatoid arthritis patients |
| Q37453985 | Determining a low disease activity threshold for decision to maintain disease-modifying antirheumatic drug treatment unchanged in rheumatoid arthritis patients |
| Q28596697 | Development of a diagnostic decision tree for obstructive pulmonary diseases based on real-life data |
| Q37591511 | Elderly onset rheumatoid arthritis: differential diagnosis and choice of first-line and subsequent therapy |
| Q41723056 | Genetic polymorphisms in key methotrexate pathway genes are associated with response to treatment in rheumatoid arthritis patients |
| Q44539907 | MTHFR gene polymorphisms and outcome of methotrexate treatment in patients with rheumatoid arthritis: analysis of key polymorphisms and meta-analysis of C677T and A1298C polymorphisms |
| Q36907694 | Matrix to predict rapid radiographic progression of early rheumatoid arthritis patients from the community treated with methotrexate or leflunomide: results from the ESPOIR cohort |
| Q31104875 | Performance of matrices developed to identify patients with early rheumatoid arthritis with rapid radiographic progression despite methotrexate therapy: an external validation study based on the ESPOIR cohort data |
| Q84808007 | Serum IgA rheumatoid factor and pyridinoline in very early arthritis as predictors of erosion(s) at two years: A simple model of prediction from a conservatively treated community‐based inception cohort |
| Q33772793 | The gap between practice and guidelines in the choice of first-line disease modifying antirheumatic drug in early rheumatoid arthritis: results from the ESPOIR cohort |
| Q51546311 | Trends in treatment strategies and the usage of different disease-modifying anti-rheumatic drugs in early rheumatoid arthritis in Finland. Results from a nationwide register in 2000-2007. |
| Q79791410 | [Rheumatoid arthritis today] |
Search more.